<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00383435</url>
  </required_header>
  <id_info>
    <org_study_id>P04229</org_study_id>
    <secondary_id>Doc ID: 3227334;</secondary_id>
    <secondary_id>Eudract No: 2006-002308-32;</secondary_id>
    <nct_id>NCT00383435</nct_id>
  </id_info>
  <brief_title>Effects of Mometasone Furoate/Formoterol Combination Versus Formoterol and Mometasone Furoate Alone in COPD (Study P04229AM4)(COMPLETED)</brief_title>
  <official_title>A Randomized, 26-Week, Placebo-Controlled Efficacy and Safety Study With a 26-Week Long-Term Safety Extension, of High- and Medium-Dose Inhaled Mometasone Furoate/Formoterol Fixed-Dose Combination Formulation Compared With Formoterol and High-Dose Inhaled Mometasone Furoate Monotherapy in Subjects With Moderate to Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, placebo-controlled, parallel-group, multi-site, double-blind study
      evaluating the efficacy of mometasone furoate/formoterol fumarate (MF/F) metered dose inhaler
      (MDI) 400/10 mcg twice daily (BID) and MF/F MDI 200/10 mcg BID compared with MF 400 mcg BID
      and F 10 mcg BID in adults at least 40 years of age, with moderate to severe chronic
      obstructive pulmonary disease (COPD). All placebo-treated subjects and active-treated

      subjects who will not participate in the safety extension will be discontinued

      and will have their Final Visit at Week 26. Subjects who continue into the

      26-week safety extension will have their Final Visit at Week 52. Efficacy will be measured by
      the mean change from Baseline to Week 13 in area under the forced expiratory volume in one
      second concentration time curve from 0 to 12 hours (FEV1 AUC[0-12hr]) and change from
      Baseline to Week 13 in AM predose FEV1.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</measure>
    <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
    <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</measure>
    <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
    <description>Endpoint was the last post-baseline non-missing result through Week 13 carried
forward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</measure>
    <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
    <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms (frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score range from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint is the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</measure>
    <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
    <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Partly Stable COPD</measure>
    <time_frame>Endpoint (26 weeks)</time_frame>
    <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or
treatment-related adverse event as determined by the investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</measure>
    <time_frame>Endpoint (26 weeks)</time_frame>
    <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more nebulized treatments/day of inhaled rescue medication. Moderate = treatment with antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">1055</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>MF/F MDI 400/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>MF MDI 400 mcg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Formoterol MDI 10 mcg BID</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo MDI BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate/formoterol (MF/F) combination</intervention_name>
    <description>MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks</description>
    <arm_group_label>MF/F MDI 400/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate/formoterol (MF/F) combination</intervention_name>
    <description>MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks</description>
    <arm_group_label>MF/F MDI 200/10 mcg BID</arm_group_label>
    <other_name>SCH 418131</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mometasone furoate MDI (MF MDI)</intervention_name>
    <description>MF 400 mcg via metered dose inhaler twice daily for 52 weeks</description>
    <arm_group_label>MF MDI 400 mcg BID</arm_group_label>
    <other_name>SCH 32088</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Formoterol MDI</intervention_name>
    <description>Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks</description>
    <arm_group_label>Formoterol MDI 10 mcg BID</arm_group_label>
    <other_name>Foradil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo MDI twice a day for 26 weeks</description>
    <arm_group_label>Placebo MDI BID</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe COPD based on prebronchodilator FEV1/forced vital capacity (FVC)
             ratio of &lt;=70%.

          -  At Screening, postbronchodilator FEV1 must be &lt;=60% predicted normal &amp; &gt;=25% predicted
             normal.

          -  COPD symptoms for &gt;=24 months.

          -  Ex- or current smoker with smoking history &gt;=10 pack years.

          -  Only albuterol/salbutamol for relief for at least 2 weeks prior to randomization.

          -  Withdraw from parenteral &amp; oral steroids, anticholinergics, &amp; antibiotics at least 4
             weeks prior to Screening.

          -  No harm in changing current COPD therapy, willing to discontinue his/her
             anticholinergics, inhaled corticosteroids (ICS) or ICS/long-acting beta agonists
             (LABA) at Screening, &amp; transferred to albuterol/salbutamol for relief for 2 weeks
             prior to randomization.

          -  Lab tests conducted at Screening must be acceptable to investigator. Electrocardiogram
             (ECG) performed at Screening Visit or within 30 days prior to Screening must be
             acceptable to investigator. Chest x-ray performed at Screening or within 12 months
             prior to Screening must be acceptable to investigator.

          -  Women who have

        been surgically sterilized or are at least 1 year postmenopausal are not

        considered to be of childbearing potential. A female subject of childbearing

        potential must have a negative serum pregnancy test at Screening in order to

        be considered eligible for enrollment. Female of childbearing potential must use birth
        control. Includes: hormonal contraceptives, intra-uterine device (IUD), condom in
        combination with spermicide, monogamous relationship with male partner who had vasectomy.
        Started birth control at least 3 months prior to Screening (exception condom), &amp; agree to
        continue. Female who is not currently sexually active must agree/consent to use a method
        should she become sexually active. Women surgically sterilized or are at least 1 year
        postmenopausal are not considered to be of childbearing potential. Female must have
        negative serum pregnancy test at Screening.

        Exclusion Criteria:

          -  Evidence (upon visual inspection) of oropharyngeal candidiasis at Baseline with or
             without treatment. If there is evidence at Screening, may be treated as appropriate &amp;
             visit can be scheduled upon resolution. If there is evidence at Baseline Visit, may be
             treated as appropriate &amp; visit can be rescheduled upon resolution.

          -  History of renal, hepatic, cardiovascular, metabolic, neurologic, hematologic,
             ophthalmological, respiratory, gastrointestinal, cerebrovascular, or other which could
             interfere with study or require treatment which might interfere with study. Examples
             include (but are not limited to) hypertension being treated with beta-blockers, active
             hepatitis, coronary artery disease, arrhythmia, significant QTc prolongation (ie QTcF
             or QTcB [Fridericia or Bazett corrections, respectively &gt;500 milliseconds (msecs)]),
             stroke, severe rheumatoid arthritis, chronic open-angle glaucoma or posterior
             subcapsular cataracts, acquired immune deficiency syndrome (AIDS), or conditions that
             may interfere with respiratory function such as asthma, bronchiectasis, cystic
             fibrosis. Others which are well-controlled &amp; stable (eg hypertension not requiring
             beta-blockers) will not prohibit participation if deemed appropriate per investigator.

          -  Allergy/sensitivity to glucocorticosteroids, beta-2 agonists, study drug/excipients.

          -  Female who is breast-feeding, pregnant, or intends to become pregnant.

          -  Illicit drug user.

          -  Human immunodeficiency virus (HIV) positive (testing not conducted).

          -  Unable to correctly use oral MDI.

          -  Taking any restricted medications prior to Screening without meeting washout.

          -  Cannot adhere to permitted concomitant &amp; prohibited medications.

          -  May not participate in this same study at another investigational site. Cannot
             participate in different investigational study at any site, during same time of study.

          -  Not be randomized into study more than once.

          -  No person directly associated with administration of study may participate.

          -  Previously participated in MF/F trial.

          -  Increase in absolute volume of &gt;=400 milliliters (mL) at Screening or prior to
             Baseline within 30 minutes after administration of 4 inhalations of
             albuterol/salbutamol (total dose of 360 to 400 mcg), or nebulized 2.5 mg
             albuterol/salbutamol.

          -  Asthma.

          -  Blood eosinophil count greater than 0.57 x 10^3/microliter (uL).

          -  Lobectomy, pneumonectomy or lung volume reduction surgery.

          -  Lung cancer.

          -  Requires long-term administration of oxygen (&gt;15 hours per day).

          -  A subject who experiences an exacerbation of COPD requiring medical

        intervention within 4 weeks prior to randomization, beta-blocking agents, or

        treatment with additional excluded medication (other than short-acting beta agonists
        (SABA)/short-acting

        anticholinergic to be used as rescue medication).

          -  alpha-1-antitrypsin deficiency.

          -  Cataract extractions on both eyes.

          -  A history and/or presence of intraocular pressure in either eye &gt;=22 millimeters of
             mercury (mm Hg), glaucoma, and/or posterior subcapsular cataracts. A subject who has
             undergone incisional or intraocular surgery in which the natural lens is still present
             in the eye. A subject with a history of penetrating trauma to both eyes. A subject
             with one or more of the following Lens Opacities Classification System (LOCS) III
             grades at screening:

        nuclear opalescence (NO): &gt;=3.0,

        nuclear color (NC): &gt;=3.0,

        cortical cataract (C): &gt;=2.0,

        posterior subcapsular (P): &gt;=0.5.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Colombia</country>
    <country>Costa Rica</country>
    <country>Croatia</country>
    <country>Denmark</country>
    <country>Guatemala</country>
    <country>Hungary</country>
    <country>India</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Peru</country>
    <country>Philippines</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Serbia</country>
    <country>Slovakia</country>
    <country>Slovenia</country>
    <country>South Africa</country>
    <country>Thailand</country>
    <country>Ukraine</country>
    <country>United States</country>
    <country>Uzbekistan</country>
    <country>Venezuela</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 29, 2006</study_first_submitted>
  <study_first_submitted_qc>September 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2006</study_first_posted>
  <results_first_submitted>July 5, 2011</results_first_submitted>
  <results_first_submitted_qc>August 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 3, 2011</results_first_posted>
  <last_update_submitted>March 13, 2017</last_update_submitted>
  <last_update_submitted_qc>March 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Mometasone Furoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>At Week 26, all participants randomized to placebo were to be discontinued, while 75% of participants randomized to an
active treatment were randomly selected to participate in the 26-week Treatment Safety Extension. Several placebo-treated participants continued in error into the Treatment Safety Extension.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MF/F MDI 400/10 mcg BID</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
        </group>
        <group group_id="P2">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="P3">
          <title>MF MDI 400 mcg BID</title>
          <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="P4">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>Placebo MDI BID for 26 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>26-Week Double-Blind Treatment Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="217"/>
                <participants group_id="P2" count="207"/>
                <participants group_id="P3" count="210"/>
                <participants group_id="P4" count="209"/>
                <participants group_id="P5" count="212"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="176"/>
                <participants group_id="P2" count="169"/>
                <participants group_id="P3" count="164"/>
                <participants group_id="P4" count="172"/>
                <participants group_id="P5" count="159"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
                <participants group_id="P2" count="38"/>
                <participants group_id="P3" count="46"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="53"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal unrelated</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="10"/>
                <participants group_id="P5" count="17"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal related</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>26-Week Treatment Safety Extension</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="131"/>
                <participants group_id="P2" count="130"/>
                <participants group_id="P3" count="124"/>
                <participants group_id="P4" count="131"/>
                <participants group_id="P5" count="13"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="117"/>
                <participants group_id="P2" count="121"/>
                <participants group_id="P3" count="108"/>
                <participants group_id="P4" count="116"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="15"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal unrelated</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="6"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant withdrawal related</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Non-compliance with protocol</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not meet protocol eligibility</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MF/F MDI 400/10 mcg BID</title>
          <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
        </group>
        <group group_id="B2">
          <title>MF/F MDI 200/10 mcg BID</title>
          <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="B3">
          <title>MF MDI 400 mcg BID</title>
          <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="B4">
          <title>F MDI 10 mcg BID</title>
          <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>Placebo MDI BID for 26 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="217"/>
            <count group_id="B2" value="207"/>
            <count group_id="B3" value="210"/>
            <count group_id="B4" value="209"/>
            <count group_id="B5" value="212"/>
            <count group_id="B6" value="1055"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="59.7" spread="9.1"/>
                    <measurement group_id="B2" value="60.9" spread="8.1"/>
                    <measurement group_id="B3" value="59.8" spread="8.9"/>
                    <measurement group_id="B4" value="59.6" spread="8.5"/>
                    <measurement group_id="B5" value="58.8" spread="8.7"/>
                    <measurement group_id="B6" value="59.8" spread="8.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="46"/>
                    <measurement group_id="B3" value="46"/>
                    <measurement group_id="B4" value="57"/>
                    <measurement group_id="B5" value="42"/>
                    <measurement group_id="B6" value="237"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="171"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="164"/>
                    <measurement group_id="B4" value="152"/>
                    <measurement group_id="B5" value="170"/>
                    <measurement group_id="B6" value="818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
        <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
        <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
        <population>Intent-to-treat (ITT) population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Area Under the Time Curve From 0 to 12 Hours (AUC(0-12 Hours)) of Change From Baseline to Week 13 in Forced Expiratory Volume (Liters) in 1 Second (FEV1)</title>
          <description>FEV1 AUC was standardized to liters. Endpoint was the last post-baseline non-missing result through Week 13 carried forward.</description>
          <population>Intent-to-treat (ITT) population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="207"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="207"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.186" spread="0.418"/>
                    <measurement group_id="O2" value="1.227" spread="0.418"/>
                    <measurement group_id="O3" value="1.255" spread="0.418"/>
                    <measurement group_id="O4" value="1.252" spread="0.418"/>
                    <measurement group_id="O5" value="1.227" spread="0.418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.166" spread="0.258"/>
                    <measurement group_id="O2" value="0.126" spread="0.258"/>
                    <measurement group_id="O3" value="0.057" spread="0.258"/>
                    <measurement group_id="O4" value="0.077" spread="0.258"/>
                    <measurement group_id="O5" value="0.003" spread="0.258"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.007</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</title>
        <description>Endpoint was the last post-baseline non-missing result through Week 13 carried
forward.</description>
        <time_frame>Baseline to Endpoint (13 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline to Week 13 Endpoint in AM Predose FEV1</title>
          <description>Endpoint was the last post-baseline non-missing result through Week 13 carried
forward.</description>
          <population>ITT population</population>
          <units>Liters</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="203"/>
                <count group_id="O3" value="206"/>
                <count group_id="O4" value="208"/>
                <count group_id="O5" value="204"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.191" spread="0.424"/>
                    <measurement group_id="O2" value="1.223" spread="0.424"/>
                    <measurement group_id="O3" value="1.258" spread="0.424"/>
                    <measurement group_id="O4" value="1.252" spread="0.424"/>
                    <measurement group_id="O5" value="1.230" spread="0.424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.111" spread="0.270"/>
                    <measurement group_id="O2" value="0.058" spread="0.270"/>
                    <measurement group_id="O3" value="0.027" spread="0.270"/>
                    <measurement group_id="O4" value="0" spread="0.270"/>
                    <measurement group_id="O5" value="-0.017" spread="0.270"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.029</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</title>
        <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms (frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score range from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint is the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
        <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Endpoint in St George's Respiratory Questionaire (SGRQ) Total Score</title>
          <description>SGRQ consisted of 76 items aggregated into 3 component scores: symptoms (frequency/severity), activity (cause or limited by breathlessness), impact (social functioning, psychological disturbances from airway disease), &amp; total score. Best health scores have a low numeric value. All component scores &amp; total score range from 0-100, with a higher score indicating greater disease burden. A 4-point increase over placebo (and Baseline) was considered the minimum clinically important difference. Endpoint is the last post-baseline non-missing result through the 26 week evaluation carried forward.</description>
          <population>ITT population</population>
          <units>Score on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="196"/>
                <count group_id="O3" value="193"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.05" spread="18.48"/>
                    <measurement group_id="O2" value="45.89" spread="18.48"/>
                    <measurement group_id="O3" value="47.00" spread="18.48"/>
                    <measurement group_id="O4" value="44.87" spread="18.48"/>
                    <measurement group_id="O5" value="44.60" spread="18.48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.43" spread="14.72"/>
                    <measurement group_id="O2" value="-5.69" spread="14.72"/>
                    <measurement group_id="O3" value="-6.99" spread="14.72"/>
                    <measurement group_id="O4" value="-6.18" spread="14.72"/>
                    <measurement group_id="O5" value="-2.87" spread="14.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>ANCOVA</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.059</p_value>
            <method>ANCOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</title>
        <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
        <time_frame>Baseline to Endpoint (26 weeks)</time_frame>
        <population>ITT population.</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Proportion of Chronic Obstructive Pulmonary Disease (COPD) Symptom-Free Nights (AM Diary Symptoms)</title>
          <description>Prior to the use of study drug rescue medication (in the morning upon awakening) the participant evaluated the COPD symptoms of wheezing, cough, and difficulty breathing. A symptom-free night was defined as a combined score of 0 (no symptoms) across all three COPD symptoms evaluated the following morning. Proportion for Baseline included data from the last week before the first dose. Proportion for Endpoint included data across the entire 26-week treatment period.</description>
          <population>ITT population.</population>
          <units>Proportion of symptom-free nights</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="213"/>
                <count group_id="O2" value="198"/>
                <count group_id="O3" value="204"/>
                <count group_id="O4" value="206"/>
                <count group_id="O5" value="205"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.31" spread="0.345"/>
                    <measurement group_id="O2" value="0.29" spread="0.345"/>
                    <measurement group_id="O3" value="0.33" spread="0.345"/>
                    <measurement group_id="O4" value="0.35" spread="0.345"/>
                    <measurement group_id="O5" value="0.31" spread="0.345"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endpoint (Change from Baseline)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" spread="0.27"/>
                    <measurement group_id="O2" value="0.07" spread="0.27"/>
                    <measurement group_id="O3" value="0.11" spread="0.27"/>
                    <measurement group_id="O4" value="0.14" spread="0.27"/>
                    <measurement group_id="O5" value="0.06" spread="0.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Partly Stable COPD</title>
        <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or
treatment-related adverse event as determined by the investigator.</description>
        <time_frame>Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Partly Stable COPD</title>
          <description>Partly stable COPD was a composite measure that included the following COPD
outcomes: (1) No oral steroid rescue medication; (2) No AM or PM COPD weekly average symptom score greater than 2 during at least 7 of 8 weeks; (3) No moderate or severe exacerbations; (4) No unscheduled visits due to COPD worsenings; (5) No study discontinuation due to treatment failure or
treatment-related adverse event as determined by the investigator.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="210"/>
                <count group_id="O4" value="209"/>
                <count group_id="O5" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="95"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="90"/>
                    <measurement group_id="O5" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</title>
        <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more nebulized treatments/day of inhaled rescue medication. Moderate = treatment with antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
        <time_frame>Endpoint (26 weeks)</time_frame>
        <population>ITT population</population>
        <group_list>
          <group group_id="O1">
            <title>MF/F MDI 400/10 mcg BID</title>
            <description>Mometasone furoate/formoterol fumarate (MF/F) 400/10 mcg via a metered dose inhaler (MDI) twice daily (BID) for 52 weeks</description>
          </group>
          <group group_id="O2">
            <title>MF/F MDI 200/10 mcg BID</title>
            <description>MF/F 200/10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O3">
            <title>MF MDI 400 mcg BID</title>
            <description>Mometasone furoate (MF) 400 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O4">
            <title>F MDI 10 mcg BID</title>
            <description>Formoterol fumarate (F) 10 mcg via a MDI BID for 52 weeks</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>Placebo MDI BID for 26 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Mild, Moderate, or Severe COPD Exacerbations</title>
          <description>Mild = 12 or more inhalations/day of inhaled rescue medication or 2 or more nebulized treatments/day of inhaled rescue medication. Moderate = treatment with antibiotics or oral steroids. Severe = emergency room treatment or hospitalizations of survival curves. If an event was composed of multiple criteria, the most severe criteria was assigned to the event.</description>
          <population>ITT population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="217"/>
                <count group_id="O2" value="207"/>
                <count group_id="O3" value="210"/>
                <count group_id="O4" value="209"/>
                <count group_id="O5" value="212"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="48"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="45"/>
                    <measurement group_id="O5" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="30"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                    <measurement group_id="O5" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>Treatment period for adverse events was 52 weeks for MF/F MDI 400/10 mcg BID, MF/F MDI 200/10 mcg BID, MF MDI 400 mcg BID, and F MDI 10 mcg BID and 26 weeks for placebo.</desc>
      <group_list>
        <group group_id="E1">
          <title>MF/F MDI 200/10 MCG BID</title>
        </group>
        <group group_id="E2">
          <title>MF/F MDI 400/10 MCG BID</title>
        </group>
        <group group_id="E3">
          <title>MF MDI 400 MCG BID</title>
        </group>
        <group group_id="E4">
          <title>F MDI 10 MCG BID</title>
        </group>
        <group group_id="E5">
          <title>PLACEBO</title>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="29" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="22" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="29" subjects_at_risk="209"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>COR PULMONALE CHRONIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>GOITRE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CATARACT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CATARACT NUCLEAR</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>GLAUCOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>LENTICULAR OPACITIES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA HAEMORRHAGIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>EROSIVE OESOPHAGITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>HERNIAL EVENTRATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL FOOD IMPACTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL RUPTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>SUDDEN DEATH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CHRONIC HEPATIC FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS LIMB</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>ARTHRITIS BACTERIAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PULMONARY TUBERCULOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>SKIN LACERATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>ADENOCARCINOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>COLON NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>EXTRANODAL MARGINAL ZONE B-CELL LYMPHOMA (MALT TYPE)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>LARYNGEAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>LUNG CANCER METASTATIC</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>LUNG NEOPLASM MALIGNANT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>MALIGNANT PALATE NEOPLASM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>NON-HODGKIN'S LYMPHOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>VASCULAR HEADACHE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="207"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="217"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="210"/>
                <counts group_id="E4" events="10" subjects_affected="10" subjects_at_risk="209"/>
                <counts group_id="E5" events="8" subjects_affected="7" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>HICCUPS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>HYPOXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PNEUMOMEDIASTINUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="2" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PULMONARY AMYLOIDOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CAROTID ENDARTERECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA REPAIR</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ARTERY ANEURYSM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
              <event>
                <sub_title>POOR PERIPHERAL CIRCULATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="207"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="217"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="210"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="209"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="207"/>
                <counts group_id="E2" events="15" subjects_affected="10" subjects_at_risk="217"/>
                <counts group_id="E3" events="21" subjects_affected="9" subjects_at_risk="210"/>
                <counts group_id="E4" events="18" subjects_affected="11" subjects_at_risk="209"/>
                <counts group_id="E5" events="22" subjects_affected="11" subjects_at_risk="212"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The investigator has the right to publish or publicly present results. The investigator agrees not to publish or publicly present any interim results without prior written consent of the sponsor. The investigator agrees to provide to the sponsor 45 days before submission for publication that report results of the study. The sponsor shall have the right to review &amp; comment with respect to publications, abstracts, slides, &amp; manuscripts &amp; the right to review &amp; comment on the data &amp; presentation.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

